首页AutophagyBTK
BTK
T1835 Ibrutinib Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T1976 RN486 RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
T2302 CNX774 CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
T2472 CGI1746 CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
T2473 PLX4720 PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
T2603 Spebrutinib Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
T3626 Acalabrutinib Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibi
T4268 CHMFL-BMX-078 CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
T6078 Saracatinib Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
T6217 LFM-A13 LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.
T6921 ONO-4059 analogue ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
T4337 PCI29732 PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
T4387 evobrutinib Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the development and functioning of
T5138 BMS986142 BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
T5407 BMS986195 BMS986195 is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for BTK).
T7584 zanubrutinib Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
TQ0039 (±)-Zanubrutinib (±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
TQ0230 BTK IN-1 BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
TQ0236 Tirabrutinib Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
TQ0242 Fenebrutinib Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
T3024 Avitinib Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic
T6918 Olmutinib Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to
T4391 Syk Inhibitor II (hydrochloride) Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates dow
T12152 N-piperidine Ibrutinib hydrochloride N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
T12311 Tirabrutinib hydrochloride Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
T12542 PRN1008 PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
T10240 ACP-5862 ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective BTK inhibitor (IC50
T14357 Spebrutinib besylate Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
T14681 BMS-935177 BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
T14692 BMX-IN-1 BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM.
T14956 CHMFL-BTK-01 CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
T15365 G-744 G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthritis.
T11379 GDC-0834
T10629 Btk inhibitor 2 Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
T16265 Naluzotan Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiety and depression and
T16441 PCI-33380 PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
T12673L PF-06250112 PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC (IC50s: 0.9 n
T16730 Remibrutinib Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibruti
T10625 IBT6A IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
T16853 SB-633825 SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 150 nM, respectively
T17098 Tilfrinib Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.
T8636 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
T12317 Orelabrutinib Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
T14323 ARQ 531 ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity, with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。